Interethnic and intraethnic variability of NAT2 single nucleotide polymorphisms

被引:70
作者
Garcia-Martin, Elena [1 ]
机构
[1] Univ Extremadura, Sch Biol Sci, Dept Biochem & Mol Biol & Genet, E-06071 Badajoz, Spain
关键词
D O I
10.2174/138920008784892155
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Genetic polymorphisms of human arylamine N-acetyltransferase 2 (NAT2) are responsible for interindividual variation in the acetylation of numerous drugs and in the transformation of aromatic and heterocyclic amines into carcinogenic intermediates. Although large interethnic variability in the frequency for NAT2 variant alleles has been reported, comparison of allele frequencies is hampered by differences in the criteria for the assignment of allelic variants. To avoid such sources of bias, in this review we analyze the occurrence of both interethnic and intraethnic variability for the seven commonest single nucleotide polymorphisms (SNP) in the NAT2 gene by using raw SNP data instead of inferred haplotypes. Besides the large interethnic variability observed for all SNPs except C282T, intraethnic variability for NAT2 SNPs was identified for the SNPs G191A among Caucasians (p<0.0001), T341C among Oriental (p<0.001) or African individuals (p<0.012), C481T among Oriental (p<0.001) or African individuals (p<0.001), and G590A among Oriental individuals (p<0.001). In contrast, no major intraethnic differences were identified for the SNPs C282T, A806G or G857A. Intraethnic variability may have relevant clinical implications. For instance, case-control NAT2 studies should not be extrapolated from one Oriental population to another. Nonsynonymous SNPs occur in 32% of alleles in Japanese individuals and in 47% of alleles in Chinese individuals, therefore the frequency of adverse effects and cancer related to slow acetylation is expected to be higher in individuals with Chinese descent than in those with Japanese descent. Intraethnic variability reinforces the need for proper selection of control subjects and points against the use of surrogate control groups for studies involving association of NAT2 alleles with adverse drug effects or spontaneous diseases.
引用
收藏
页码:487 / 497
页数:11
相关论文
共 67 条
[1]  
AGUNDEZ J, 2008, CLIN CHEM IN PRESS
[2]   MOLECULAR ANALYSIS OF THE ARYLAMINE N-ACETYLTRANSFERASE POLYMORPHISM IN A SPANISH POPULATION [J].
AGUNDEZ, JAG ;
MARTINEZ, C ;
OLIVERA, M ;
LEDESMA, MC ;
LADERO, JM ;
BENITEZ, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (02) :202-209
[3]   PREVALENCE OF CYP2D6 GENE DUPLICATION AND ITS REPERCUSSION ON THE OXIDATIVE PHENOTYPE IN A WHITE-POPULATION [J].
AGUNDEZ, JAG ;
LEDESMA, MC ;
LADERO, JM ;
BENITEZ, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (03) :265-269
[4]   CYP2D6, NAT2 and CYP2E1 genetic polymorphisms in nonagenarians [J].
Agundez, JAG ;
Rodriguez, I ;
Olivera, M ;
Ladero, JM ;
Garcia, MA ;
Ribera, JM ;
Benitez, J .
AGE AND AGEING, 1997, 26 (02) :147-151
[5]   Glutathione S-transferase GSTT1 and GSTM1 allozymes:: beyond null alleles [J].
Agundez, Jose A. G. ;
Ladero, Jose M. .
PHARMACOGENOMICS, 2008, 9 (03) :359-363
[6]   NAT2 polymorphism in Omani gastric cancer patients-risk predisposition and clinicopathological associations [J].
Al-Moundhri, Mansour S. ;
Al-Kindi, Mohamed ;
Al-Nabhani, Maryam ;
Al-Bahrani, Bassim ;
Burney, Ikram A. ;
Al-Madhani, Ali ;
Ganguly, Shyam S. ;
Tanira, Misbah .
WORLD JOURNAL OF GASTROENTEROLOGY, 2007, 13 (19) :2697-2702
[7]   N-acetyltransferase polymorphism among northern Sudanese [J].
Al-Yahyaee, Said ;
Gaffar, Uzma ;
Al-Ameri, Maryam M. ;
Qureshi, Mansoor ;
Zadjali, Fahad ;
Ali, Baderldin H. ;
Bayoumi, Raid .
HUMAN BIOLOGY, 2007, 79 (04) :445-452
[8]   A haplotype map of the human genome [J].
Altshuler, D ;
Brooks, LD ;
Chakravarti, A ;
Collins, FS ;
Daly, MJ ;
Donnelly, P ;
Gibbs, RA ;
Belmont, JW ;
Boudreau, A ;
Leal, SM ;
Hardenbol, P ;
Pasternak, S ;
Wheeler, DA ;
Willis, TD ;
Yu, FL ;
Yang, HM ;
Zeng, CQ ;
Gao, Y ;
Hu, HR ;
Hu, WT ;
Li, CH ;
Lin, W ;
Liu, SQ ;
Pan, H ;
Tang, XL ;
Wang, J ;
Wang, W ;
Yu, J ;
Zhang, B ;
Zhang, QR ;
Zhao, HB ;
Zhao, H ;
Zhou, J ;
Gabriel, SB ;
Barry, R ;
Blumenstiel, B ;
Camargo, A ;
Defelice, M ;
Faggart, M ;
Goyette, M ;
Gupta, S ;
Moore, J ;
Nguyen, H ;
Onofrio, RC ;
Parkin, M ;
Roy, J ;
Stahl, E ;
Winchester, E ;
Ziaugra, L ;
Shen, Y .
NATURE, 2005, 437 (7063) :1299-1320
[9]   Arylamine N-acetyltransferase (NAT2) genotypes in a Turkish population [J].
Aynacioglu, AS ;
Cascorbi, I ;
Mrozikiewicz, PM ;
Roots, I .
PHARMACOGENETICS, 1997, 7 (04) :327-331
[10]   Arylamine N-acetyltransferase 2 slow acetylator polymorphisms in unrelated Iranian individuals [J].
Bakayev, VV ;
Mohammadi, F ;
Bahadori, M ;
Sheikholslami, M ;
Javeri, A ;
Masjedi, MR ;
Velayati, AA .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 60 (07) :467-471